Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) insider Christopher Heery sold 18,168 shares of the business's stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $51.33, for a total transaction of $932,563.44. Following the completion of the transaction, the insider now owns 8,938 shares in the company, valued at $458,787.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Christopher Heery also recently made the following trade(s):
- On Friday, March 22nd, Christopher Heery sold 41,365 shares of Arcellx stock. The stock was sold at an average price of $70.18, for a total transaction of $2,902,995.70.
- On Tuesday, March 26th, Christopher Heery sold 5,450 shares of Arcellx stock. The shares were sold at an average price of $69.11, for a total value of $376,649.50.
- On Monday, February 12th, Christopher Heery sold 2,967 shares of Arcellx stock. The shares were sold at an average price of $64.46, for a total value of $191,252.82.
- On Thursday, February 8th, Christopher Heery sold 3,456 shares of Arcellx stock. The stock was sold at an average price of $62.29, for a total value of $215,274.24.
Arcellx Price Performance
Shares of Arcellx stock opened at $52.69 on Friday. The company has a 50 day simple moving average of $63.02 and a two-hundred day simple moving average of $56.17. The firm has a market cap of $2.81 billion, a PE ratio of -35.84 and a beta of 0.24. Arcellx, Inc. has a 1 year low of $30.74 and a 1 year high of $75.10.
Shocking $16T Elon Musk Crypto Leak
From Crypto 101 Media | Ad
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market.
Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account."
Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Click here now to get your copy.
Arcellx (NASDAQ:ACLX - Get Free Report) last announced its earnings results on Wednesday, February 28th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.95. Arcellx had a negative net margin of 64.08% and a negative return on equity of 20.96%. The company had revenue of $63.15 million during the quarter, compared to analyst estimates of $20.07 million. During the same period in the previous year, the business earned ($0.76) earnings per share. As a group, research analysts anticipate that Arcellx, Inc. will post -1.69 earnings per share for the current year.
Analyst Ratings Changes
ACLX has been the topic of a number of research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $81.00 price objective on shares of Arcellx in a report on Thursday, April 11th. HC Wainwright upped their price target on shares of Arcellx from $60.00 to $82.00 and gave the company a "buy" rating in a research note on Thursday, February 29th. Canaccord Genuity Group lifted their price objective on shares of Arcellx from $66.00 to $85.00 and gave the company a "buy" rating in a research note on Thursday, February 29th. Morgan Stanley began coverage on Arcellx in a research note on Thursday, March 7th. They set an "overweight" rating and a $81.00 price objective on the stock. Finally, Scotiabank restated an "outperform" rating and issued a $82.00 target price on shares of Arcellx in a research note on Thursday, April 4th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $75.64.
View Our Latest Stock Analysis on Arcellx
Hedge Funds Weigh In On Arcellx
Institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its position in Arcellx by 98.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,248 shares of the company's stock worth $45,000 after buying an additional 619 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of Arcellx by 5.6% in the 3rd quarter. Amalgamated Bank now owns 5,772 shares of the company's stock worth $207,000 after acquiring an additional 308 shares during the last quarter. Simplicity Wealth LLC bought a new stake in shares of Arcellx in the 1st quarter worth approximately $232,000. Exchange Traded Concepts LLC boosted its stake in shares of Arcellx by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 4,241 shares of the company's stock valued at $235,000 after purchasing an additional 1,076 shares in the last quarter. Finally, Corton Capital Inc. bought a new position in shares of Arcellx during the 3rd quarter valued at $270,000. 96.03% of the stock is currently owned by institutional investors.
Arcellx Company Profile
(
Get Free Report)
Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
